NO995683L - Vitamin D analoger og deres neuronale effekter - Google Patents

Vitamin D analoger og deres neuronale effekter

Info

Publication number
NO995683L
NO995683L NO995683A NO995683A NO995683L NO 995683 L NO995683 L NO 995683L NO 995683 A NO995683 A NO 995683A NO 995683 A NO995683 A NO 995683A NO 995683 L NO995683 L NO 995683L
Authority
NO
Norway
Prior art keywords
analogues
vitamin
nerve cells
low
present
Prior art date
Application number
NO995683A
Other languages
English (en)
Other versions
NO995683D0 (no
Inventor
Susan Carswell
Fredrik Bjoerkling
Pawel Dobrzanski
Lise Binderup
Matthew S Miller
Original Assignee
Cephalon Inc
Leo Pharm Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc, Leo Pharm Prod Ltd filed Critical Cephalon Inc
Publication of NO995683D0 publication Critical patent/NO995683D0/no
Publication of NO995683L publication Critical patent/NO995683L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse er blant annet rettet mot fremgangsmåter for anvendelse av lavkalsemiske vitamin D-analoger. Foreliggende oppfinnelse er spesielt rettet mot anvendelse av lavkalsemiske vitamin D-analoger for behandling av neurodegenerative sykdommer og forstyrrelser, for å gjøre endogen dannelse av neurotrofiske faktorer lettere, for å inhiberer nedbrytning, dysfunksjon eller tap av nerveceller, og/eller for å forøke fenotypen av nerveceller eller neuron-utløpere.
NO995683A 1997-05-22 1999-11-19 Vitamin D analoger og deres neuronale effekter NO995683L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4739197P 1997-05-22 1997-05-22
PCT/US1998/010480 WO1998052574A1 (en) 1997-05-22 1998-05-21 Vitamin d analogues and their neuronal effects
US09/082,762 US6207656B1 (en) 1997-05-22 1998-05-21 Vitamin D analogues and their neuronal effects

Publications (2)

Publication Number Publication Date
NO995683D0 NO995683D0 (no) 1999-11-19
NO995683L true NO995683L (no) 2000-01-19

Family

ID=26724967

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995683A NO995683L (no) 1997-05-22 1999-11-19 Vitamin D analoger og deres neuronale effekter

Country Status (8)

Country Link
US (1) US6207656B1 (no)
EP (1) EP1011683A4 (no)
JP (1) JP2002513416A (no)
KR (1) KR20010012770A (no)
AU (1) AU728037B2 (no)
CA (1) CA2290772A1 (no)
NO (1) NO995683L (no)
WO (1) WO1998052574A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1206448T3 (da) * 1999-08-04 2004-08-09 Leo Pharma As Nye vitamin D analoger
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US20030118536A1 (en) * 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
JP4520309B2 (ja) * 2002-09-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション 選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−２−Ｈ−ナフト［１，２−ｆ］インドール−４−カルボキサミド誘導体
AR041696A1 (es) * 2002-10-23 2005-05-26 Leo Pharm Prod Ltd Compuestos analogos de vitamina d, composiciones que comprenden dichos compuestos analogos y su uso
US20060171983A1 (en) * 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
US20050209203A1 (en) * 2003-07-30 2005-09-22 Jin Tian Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
AU2006239883A1 (en) * 2005-04-22 2006-11-02 Novacea, Inc. Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof
CA2622761A1 (en) * 2005-09-16 2007-03-22 Coley Pharmaceutical Gmbh Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
BRPI0622298A8 (pt) * 2005-11-25 2016-04-05 Coley Pharm Gmbh Oligorribonucleotídeo para estimular a produção de uma citocina pró-inflamatória, uso do mesmo e composição contendo tal oligorribonucleotídeo
US8377913B2 (en) * 2007-11-20 2013-02-19 Abbvie Inc. Vitamin D receptor activators and methods of making
SG2014006324A (en) 2009-01-27 2014-03-28 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
WO2010088409A2 (en) * 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
NZ595727A (en) * 2009-04-17 2013-11-29 Vidasym Inc Vitamin d receptor agonists and uses thereof
CN106265695B (zh) 2009-08-14 2021-05-07 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
US20140296190A1 (en) * 2013-03-27 2014-10-02 Dsm Ip Assets B.V. Marketing the use of 25-hydroxyvitamin d3 to enhance cognition
NZ714801A (en) 2013-05-29 2021-07-30 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010351A1 (en) 1988-04-21 1989-11-02 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis Novel vitamin d analogues
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB9007236D0 (en) 1990-03-30 1990-05-30 Leo Pharm Prod Ltd Chemical compounds
GB9206648D0 (en) 1992-03-26 1992-05-06 Leo Pharm Prod Ltd Chemical compounds
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
GB9314400D0 (en) 1993-07-12 1993-08-25 Leo Pharm Prod Ltd Produktionsaktieselskab) chemical compounds
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
GB9325415D0 (en) * 1993-12-13 1994-02-16 Res Inst Medicine Chem Chemical compounds
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5716946A (en) 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment

Also Published As

Publication number Publication date
EP1011683A4 (en) 2003-06-11
CA2290772A1 (en) 1998-11-26
US6207656B1 (en) 2001-03-27
JP2002513416A (ja) 2002-05-08
EP1011683A1 (en) 2000-06-28
AU728037B2 (en) 2001-01-04
WO1998052574A1 (en) 1998-11-26
AU7691798A (en) 1998-12-11
NO995683D0 (no) 1999-11-19
KR20010012770A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
NO995683L (no) Vitamin D analoger og deres neuronale effekter
BR9908222A (pt) Composições para regular a aparência da pele
CA2282654A1 (en) Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder
BR9710689A (pt) Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia
AU7467496A (en) Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
AU2428292A (en) Treatment of endocrine disorders by nerve stimulation
IL121170A0 (en) Compositions for the treatment of dermatological disorders
WO1999045949A3 (en) Use of follistatin to modulate gdf-8 and bmp-11
CA2242865A1 (en) Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
WO2000038717A3 (en) Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia
NO993979L (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
WO1997015300A3 (de) Verwendung von 4-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
EP0820467A4 (en) METHODS OF TREATING EYE DISORDERS
BG99177A (en) New 7 -substituted-4-aza-5 - cholestanones as inhibitors of 5 - reductase
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
BR9808606A (pt) Materiais e métodos para tratamento de doenças com ribozimas
WO1998020880A3 (en) 11-Halo prostaglandins for the treatment of glaucoma or ocular hypertension
AU569920B2 (en) Administration of gangliosides by inhalation
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
HUP0203371A2 (hu) Adenozinreceptor antagonisták, eljárás ezek előállítására és alkalmazásuk
BG102342A (en) Optical active derivative of phenylpyrimidine as an anlgesics
WO2004064766A3 (en) Method of treatment of conditions by administration of streptolysin o
HK1112738A1 (en) Arylsulfonamides and analogues as well as use for the treatment of neuro- degenerative disorders